[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100643528","phase-4-evaluation-of-the-clinical-impact-of-adjunctive-l-carnitine-therapy-in-critically-ill-hepatic-patients-admitted-to-intensive-care-unit-100643528",false,"NCT07642076","Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit","Inclusion Criteria:\n\n* Age more than 18 years old\n* male or female with confirmed liver disease admitted to intensive care unit, including:\n* Acute-on-chronic liver failure (ACLF)\n* Hepatic encephalopathy\n* spontaneous bacterial peritonitis (SBP)\n* variceal bleeding\n* fulminant hepatitis\n* Hepatorenal syndrome\n* Ascites\n* Etc\n\nExclusion Criteria:\n\n* Age of less than 18 years old\n* Pregnancy or Lactation\n* patients have seizure\n* patient on warfarin","ALL","18 Years",{"count":18,"type":19},58,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.",[25],"Hepatic","NOT_YET_RECRUITING","2026-06-07",{"date":29,"type":30},"2026-06-11","ACTUAL",{"date":32,"type":19},"2026-06",{"date":34,"type":19},"2027-03",{"name":36,"class":37},"Beni-Suef University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":20,"phases":46,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":61},"100467038","stereotactic-liver-ablation-assisted-with-intra-arterial-ct-hepatic-arteriography-and-ablation-confirmation-software-assessment-stereolab-100467038","NCT05361551","Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)","Inclusion Criteria:\n\n1. Patients presenting with up to 5 colorectal liver metastasis measuring up to 5 cm who are referred to percutaneous ablation;\n2. Ability to completely cover the target tumor with at least a 5 mm ablation margin as determined per pre-procedure cross-sectional imaging;\n3. Distance to central bile ducts \\> 1 cm;\n4. Adequate glomerular filtration rate (GFR \\> 40) and no severe allergies to iodine contrast-media;\n5. Ability to understand and the willingness to sign written informed consent;\n6. Age \\> 18 years-old;\n7. Performance status 0-2 (Eastern Cooperative Oncology Group Classification \\[ECOG\\]);\n8. Expected survival \\> 12 months.\n\nExclusion Criteria:\n\n1. Use of other prior or concomitant local therapy at the target tumor(s).\n2. Active bacterial infection or fungal infection on the day of the ablation.\n3. Platelet \\\u003C 50,000\u002Fmm3.\n4. INR \\> 1.5\n5. Patients with uncorrectable coagulopathy.\n6. Currently breastfeeding or pregnant (latter confirmed by serum pregnancy test).\n7. Physical or psychological condition which would impair study participation.\n8. ASA (American Society of Anesthesiologists) score of ≥ 4.\n9. Any other loco-regional therapies at the target lesion(s).\n10. Anatomical variations in the arterial-hepatic blood supply of the liver that preclude the use of CTHA imaging.",{"count":45,"type":19},50,[47],"NA","To achieve adequate tumor treatment coverage with sufficient minimal ablation margins, several steps are required: firstly, it is critical to define tumor boundaries and extent on intra-procedural CT image; secondly, accurate planning, targeting, and confirmation of ablation probe placement within the tumor; thirdly, the use of an intra-procedural imaging assessment method to evaluate minimal ablation margins is required to define whether sufficient minimal ablation margins was obtained or if additional ablation is needed. Taking all together, those factors points to the need of having a high-precision ablation methodology for intra-procedural planning, monitoring, and ablation margin assessment. Currently, such methods are only utilized in isolation and the benefit of a combined and standardized procedure workflow is unknown. Therefore, our primary goal of this single-arm clinical trial is to investigate the technical efficacy of a high-precision liver ablation technique comprised by stereotactic-guidance, CT during hepatic arteriography-based imaging analysis, and computer-based software assessment of ablation margins for the treatment of patients referred to ablation for the treatment of primary and secondary liver cancers.",[50,25],"Liver Ablation","RECRUITING","2026-04-14",{"date":54,"type":30},"2026-04-17",{"date":56,"type":30},"2023-02-21",{"date":58,"type":19},"2026-08-31",{"name":60,"class":37},"M.D. Anderson Cancer Center",1]